59
/
1
Min Read
Thyrocare Technologies has reported a strong financial performance for the first quarter ended June 30, 2027 (Q1FY27), driven by sustained momentum in its pathology business and continued focus on profitable growth.
The company posted consolidated revenue of ₹240.02 crore, marking a 24% year-on-year (YoY) increase. Growth was primarily led by its Pathology segment, which recorded a 26% YoY rise during the quarter.
Operational performance also remained robust, with EBITDA increasing 34% YoY to ₹77.27 crore, reflecting improved operating efficiencies and healthy business momentum. Profitability strengthened further as Profit After Tax (PAT) surged 34% YoY to ₹51.33 crore, underlining the company's disciplined execution and focus on delivering sustainable earnings growth.
The strong quarterly performance highlights Thyrocare's continued expansion in the diagnostics market, supported by growing demand for pathology services and operational efficiencies that have translated into higher margins and profitability. The company remains focused on strengthening its diagnostic offerings while capitalising on the increasing demand for preventive healthcare services across the country.
This article was originally
published by the Franchiseindia.com. To read the full version,
visit here 
